Joint distribution of lipoprotein cholesterol classes. The Framingham study. 1983

R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue

During the period 1971 to 1975, the cholesterol content of lipoprotein density classes were measured in 2415 male and female Framingham Heart Study participants and 4342 of their offspring and offspring spouses who were free of coronary heart disease. In this first of three papers, the univariate and bivariate distributions of high density lipoprotein cholesterol, low density lipoprotein cholesterol, and very low density lipoprotein cholesterol are presented. There are differences in the levels of lipoprotein cholesterols by age, gender, and use of hormone preparations. The bivariate cross-tabulations of the three pairs of lipoprotein cholesterol measurements exhibit properties that cannot be appreciated from univariate summary statistics and suggest the importance of joint consideration of different lipoprotein cholesterol patterns for assessing the risk of coronary heart disease.

UI MeSH Term Description Entries
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008078 Cholesterol, LDL Cholesterol which is contained in or bound to low density lipoproteins (LDL), including CHOLESTEROL ESTERS and free cholesterol. LDL Cholesterol,Cholesteryl Linoleate, LDL,LDL Cholesteryl Linoleate,Low Density Lipoprotein Cholesterol,beta-Lipoprotein Cholesterol,Cholesterol, beta-Lipoprotein,beta Lipoprotein Cholesterol
D008079 Lipoproteins, VLDL A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues. Pre-beta-Lipoprotein,Prebeta-Lipoprotein,Prebeta-Lipoproteins,Very Low Density Lipoprotein,Very-Low-Density Lipoprotein,Very-Low-Density Lipoproteins,Lipoprotein VLDL II,Lipoproteins, VLDL I,Lipoproteins, VLDL III,Lipoproteins, VLDL1,Lipoproteins, VLDL2,Lipoproteins, VLDL3,Pre-beta-Lipoproteins,Lipoprotein, Very-Low-Density,Lipoproteins, Very-Low-Density,Pre beta Lipoprotein,Pre beta Lipoproteins,Prebeta Lipoprotein,Prebeta Lipoproteins,VLDL Lipoproteins,VLDL1 Lipoproteins,VLDL2 Lipoproteins,VLDL3 Lipoproteins,Very Low Density Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen

Related Publications

R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
October 1980, Metabolism: clinical and experimental,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
January 1988, Arteriosclerosis (Dallas, Tex.),
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
January 1988, Arteriosclerosis (Dallas, Tex.),
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
June 1998, Clinical chemistry,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
July 1999, Clinical chemistry,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
February 2021, Journal of the American Heart Association,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
April 2010, BMC medical genetics,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
August 1981, Canadian journal of biochemistry,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
September 2020, Journal of the American Heart Association,
R D Abbott, and R J Garrison, and P W Wilson, and F H Epstein, and W P Castelli, and M Feinleib, and C LaRue
January 1994, Journal of lipid research,
Copied contents to your clipboard!